Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

157.46 -1.92 (-1.20%)
Official Closing Price Updated: 4:15 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Top Thematic ETF Ideas For 2024
With AI adoption and spending expected to expand this year, new avenues for business growth will open up for tech companies beyond the Magnificent Seven. 
Via Talk Markets
Topics Artificial Intelligence ETFs
Bullish Continuation In '24? 3 Market Areas To Watch
This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
Via Talk Markets
Markets: Week 1 Week 2 - What's Next Week 3?
The growth space is getting crowded again, while the 
Via Talk Markets
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year. 
Via Talk Markets
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What's Driving Markets Wednesday?
The early 2024 sell-off is intensifying on Wall Street, with all major stock averages in the red on the second trading day of 2024. 
Via Benzinga
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Wall Street kicked off 2024 on a weaker note, with the S&P 500 dipping by 0.5%, and the Nasdaq 100 experiencing a 1.4% decline in midday trading in New York. 
Via Benzinga
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
Wall Street Sees Post-Holiday Gains, Oil Rallies, Intel Leads: What's Driving Markets Tuesday?
The U.S. stock market saw modest gains in a session characterized by low trading volumes following the Christmas holiday. The S&P 500 Index gained 0.3% during midday trading in New York, eyeing its... 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
US Stocks Bounce; Chipmakers, Cruise Lines Lead, Dollar Falls: What's Driving Markets Thursday?
On Thursday, Wall Street rebounded into positive territory, following a brief dip experienced on Wednesday. At midday trading New York time, all major stock indices were trading in the green as traders... 
Via Benzinga
Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?
Stocks inched higher during midday trading in New York on Wednesday, with the momentum carrying over from the previous day when the tech-heavy Nasdaq 100 achieved fresh record highs. 
Via Benzinga
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
MarketBeat Week in Review – 12/4 - 12/8
Stocks finished in the green to close the week; investors believe the jobs report will allow the Fed to leave interest rates unchanged when they meet next week 
Via MarketBeat
Topics Economy
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Biotech reversal confirmed: what's ahead for the IBB?
The recent reversal and reclaim of the significant $124 support level in the IBB holds importance, indicating a potential shift in momentum. 
Via MarketBeat
Topics ETFs
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
You Don't Have to Pick a Winner in Biotech. Here's Why.
If you invest over the long term, you'll increase your chances of victory. 
Via The Motley Fool
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield...
The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at... 
Via Talk Markets
Topics Economy
When News Moves So Fast, Stocks Can Stand Still
As far as the market goes, it feels like time is standing still. 
Via Talk Markets
Johnson & Johnson Stock: Is Now the Time to Sell?
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff 
Via InvestorPlace
Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up
Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment. 
Via Talk Markets
Fresh Look At Long Bonds
As long as the S&P 500 outperforms long bonds (TLT) risk is on. 
Via Talk Markets
Topics Bonds Stocks
Healthcare Playbook Revisited - Growth Plus Value
Despite concerns about rising healthcare costs and ever more expensive technology for treatment encompassing drugs, devices, and data management, still innovative medicine marches on. 
Via Talk Markets
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Technical Correction Or Return Of The Bear Market?
The QQQ chart right now has a few key aspects. 
Via Talk Markets
It’s Really All About the Retail Sector Now
Should XRT break the July calendar range low, we will once again be talking about the 80-month moving average or the 6–7-year business cycle low. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.